Search Results

You are looking at 21 - 30 of 595 items for :

  • "surveillance" x
Clear All
Full access

Heather Hampel

implications for surveillance and treatment. MSI-positive patients have a better prognosis 1 but do not seem to benefit from 5-fluorouracil-based chemotherapy. 2 In the future, these patients may be candidates for new therapies. The need to identify which

Full access

Ayal A. Aizer, Xiangmei Gu, Ming-Hui Chen, Toni K. Choueiri, Neil E. Martin, Jason A. Efstathiou, Andrew S. Hyatt, Powell L. Graham, Quoc-Dien Trinh, Jim C. Hu and Paul L. Nguyen

is often overtreated in the United States, as the 10-year disease-specific mortality rate for appropriately selected patients managed with active surveillance approaches 0%, 3 – 5 and a recently published randomized clinical trial showed no survival

Full access

Anya Litvak, Andrea Cercek, Neil Segal, Diane Reidy-Lagunes, Zsofia K. Stadler, Rona D. Yaeger, Nancy E. Kemeny, Martin R. Weiser, Melissa S. Pessin and Leonard Saltz

, 5 Since shortly after its discovery, CEA level has been widely used as a surveillance tool in patients after curative-intent resection of a colorectal cancer (CRC) primary. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for

Full access

Steven G. Waguespack and Gary Francis

contrast as part of their preoperative staging, waiting 2 to 3 months or confirming normal 24-hour urinary iodine values before performing a diagnostic thyroid scan is advisable. Figure 2 Approach to surveillance and treatment in pediatric patients

Full access

Hans F. Schoellhammer, Gagandeep Singh and Lucille Leong

CEA after resection has decreased to 0.5 ng/mL, and remains low. Postoperative CT shows enlargement of the left lobe of the liver, and no evidence of metachronous disease ( Figure 3 ). Surveillance will consist of history and physical examination with

Full access

Ghadeer Olleik, Wassim Kassouf, Armen Aprikian, Jason Hu, Marie Vanhuyse, Fabio Cury, Stuart Peacock, Elin Bonnevier, Ebba Palenius and Alice Dragomir

need immediate treatment, up to 60% of patients diagnosed with PCa according to current practice can be managed safely with active surveillance (AS). 16 Thus, significant efforts have been made to find new tests and interventions that can differentiate

Full access

Ashley E. Ross

or pT3 disease at radical prostatectomy. Oncotype DX is intended to evaluate biopsies in men with low- or low-intermediate–risk disease managed on active surveillance. The performance of Oncotype DX has not yet been reported in active surveillance

Full access

Shilpa Grover and Sapna Syngal

unclear pathogenic significance is found, genetic test results are considered indeterminate or uninformative. Individuals with indeterminate results are still considered at higher-than-average risk, and recommendations for surveillance must be based on

Full access

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke and Sandy Srinivas

thrombosis. 111 The risk factors for development of ATE in patients treated with VEGF/VEGFR have not been clearly identified. Therefore, clinicians must be aware of the possibility of increased ATE in select patients and provide continued surveillance. Other

Full access

Peter H. Carroll and James L. Mohler

MRI. Further, they support the use of active surveillance in men identified to have low-risk cancers, linked to and compliant with the NCCN Guidelines for Prostate Cancer. Dr. Carroll acknowledged that in the 1990s and 2000s, routine screening was